Hypothesis

Cytosine drives evolution of SARS-CoV-2

Antoine Danchin and Philippe Marlrière

1Kodikos Labs, 24 rue Jean Baldassini, 69007 Lyon/Institut Cochin, 75013 Paris, France.
2TESSI, The European Syndicate of Synthetic Scientists and Industrialists, 81 rue Réaumur, 75002, Paris, France.

Summary

In this article, we show, in the specific case of SARS-CoV-2, that the role of cytosine-based metabolites used as cell growth coordinators is central to understanding both innate antiviral immunity and the evolution of the virus. An outbreak of atypical pneumonia, first noticed in Wuhan, Hubei province, China (Huang et al., 2020), developed into the COVID-19 pandemic (Jee, 2020) that displayed alarming similarities to symptoms caused by other β-coronaviruses (β-CoVs), SARS (Turinici and Danchin, 2007) and MERS (Birmingham et al., 2012) in particular. To contain the epidemic, efforts have been placed on diagnostic (Udugama et al., 2020), epidemiology (Park et al., 2020), vaccines (Zhang et al., 2020) and exploration of the use of old drugs to act as antiviral drugs (Du and Chen, 2020). Yet, all these endeavours underline an anthropocentric point of view that does not take properly into account the biology of the virus. We propose here that understanding at the molecular level how the virus multiplies and evolves in the metabolic context of its host may uniquely provide us with out-of-the-box solutions to fight the disease. To be sure, it is critical and urgent to be able to try and anticipate the future of the organism as it adapts to Homo sapiens.

The multiplication of β-CoVs requires unique interactions with the host cell. Upon internalization, the virus is stripped of its envelope and, mistaken for a messenger RNA, its positive sense RNA genome is immediately translated into an RNA-dependent RNA polymerase (replicase) and proteins that allow it to hijack relevant host functions. This involves an intricate series of events, beginning with replication of the virus into a complementary RNA template that serves to generate both new viral genomes and several individual transcripts of that template (Sawicki et al., 2007; Chen et al., 2020). As an immediate demand, the virus must access the pool of ribonucleoside triphosphates needed for the transcription of 50–100 copies of the replicated RNA strand produced at each multiplication cycle. This makes the viral sequence highly sensitive to the idiosyncrasies of nucleotide metabolism. We thus expect that the cell’s nucleotide general makeup will shape virus evolution as it inevitably mutates when producing its large progeny. Coronaviruses have evolved a specific family of functions meant to overcome some of this limitation via a proofreading step coupled to the function of its RNA replicase (Sexton et al., 2016). Yet, mutations remain unavoidable and viruses, which generate a huge number of particles within a single patient, will progressively integrate the various types of selection pressure that each virus variant faces. Selection pressure via efficacy of transmission multiplied by number of replicates per cell and selection pressure via intracellular availability of essential precursors (nucleotides, lipids, amino acids, carbohydrates) create a variety of bottlenecks for viral evolution (Kutnjak et al., 2017; Ambías et al., 2018; Orton et al., 2020). A second key feature of β-CoVs is that they are enveloped. Furthermore, some proteins of the virion are glycosylated, which involves tapping into the cell’s resources of UDP-sugars (Wellen and Thompson, 2012; Mayer et al., 2019). Besides this uracil metabolism-dependent protein-tagging feature, we focus here on the phospholipids of the membranes, which also derive from metabolites involving pyrimidines, specifically from CDP-containing liponucleotides (Kuo et al., 2016; Woods et al., 2016; Lee and Ridgway, 2020).

Briefly, we note that virus proliferation consists of reproduction of molecular sets whose chemical composition diverges grossly from the cell’s average mRNA composition, already impacted by that of average nucleotide availability (Traut, 1994; Fig. 1). We highlight here the role of cytosine-based metabolites—and consequently that of guanine-based nucleotides—as critical coordinators of the
global cell metabolism. We also document its likely consequence on the evolution of the virus. By definition, metabolism encompasses all chemical reactions connecting a limited panel of molecules so as to convert nutrients into cells. As parasites, viruses—especially those with small genomes, such as RNA viruses—do not generally code for functions that result in the construction of metabolic pathways. As a consequence, the chemical constituents of viruses derive from precursors obtained from food through metabolic reaction steps, all but a few encoded in the host cell’s genome. The question thus arises about the adequacy between the virus genome-encoded biocatalysts that perform all stages of its proliferation, on the one hand, and, on the other hand, the chemical composition of viruses as infectious vectors, whose total quantity is to be maximized for the virus to be successful. Here we (i) highlight the deviation of SARS-COV-2 RNA chemical composition compared with that of its human host; (ii) formulate a hypothesis grounded on the canonical organization of cytosine metabolism as a way to coordinate non-homothetic growth of cells—i.e., the simultaneous growth of the cytoplasm (three dimensions), the membrane (two dimensions) and the genome (one dimension)—, and point out the emergence of the endogenous antinucleotide viperin as a cognate adaptive metabolite and (iii) predict evolutionary trends of the virus results from a replication process incorporating complementary nucleotides. This process is amplified in the form of 50–100 copies, in a highly unsymmetrical operation, but this does not affect the pressure on the final guanine content.

**Cytosine as an integrator for non-homothetic growth**

To understand how viruses tap in the host’s metabolic resources, allowing non-homothetic growth in a stable manner as cells multiply, it is critical to understand how the construction of the cell’s building blocks is coordinated to allow matching the growth of its cytoplasm (three dimensions), with the growth of its envelope (two dimensions) and the growth of its genetic setup (one dimension). We propose here that the selection of a specific subset of intermediary metabolites took place in the course of evolution as a way to smooth out non-homothetic growth. Briefly, among a variety of alternatives, cytosine nucleotides ended up as the coordinating metabolites, tying up growth of the cell’s genome and of its membrane to central metabolism (Fig. 2). To be sure, de novo synthesis of nucleotides allows direct production of all triphosphates, including cytidine triphosphate (CTP). Nevertheless, there might remain perspectives for functions that result in the construction of metabolic pathways. As a consequence, the chemical constituents of viruses derive from precursors obtained from food through metabolic reaction steps, all but a few encoded in the host cell’s genome. The question thus arises about the adequacy between the virus genome-encoded biocatalysts that perform all stages of its proliferation, on the one hand, and, on the other hand, the chemical composition of viruses as infectious vectors, whose total quantity is to be maximized for the virus to be successful. Here we (i) highlight the deviation of SARS-COV-2 RNA chemical composition compared with that of its human host; (ii) formulate a hypothesis grounded on the canonical organization of cytosine metabolism as a way to coordinate non-homothetic growth of cells—i.e., the simultaneous growth of the cytoplasm (three dimensions), the membrane (two dimensions) and the genome (one dimension)—, and point out the emergence of the endogenous antinucleotide viperin as a cognate adaptive metabolite and (iii) predict evolutionary trends of the virus results from a replication process incorporating complementary nucleotides. This process is amplified in the form of 50–100 copies, in a highly unsymmetrical operation, but this does not affect the pressure on the final guanine content.

**General features of the nucleotide build-up of SARS-CoV-2 in its cellular context**

A striking feature of SARS-CoV-2 is that its genome appears to be depleted of cytosine nucleotides, pointing out an avoidance of cytosine as a most salient feature of its build-up. Because replication of the virus depends on

---

**Fig. 1.** Compositional biases human mRNA vs (+)SARS-CoV-2. The histogram of the compositional difference between *Homo sapiens* mRNAs and the SARS-CoV-2 genome shows a considerable counterselection for the presence of cytosine (and guanine) nucleotides. The figure plots the $\log_2[v(i)/h(i)]$ ratio of the content in the virus over the content in human cytoplasmic mRNAs.
some persisting negative trend against C, because CTP derives from uridine triphosphate (UTP) in a step that both requires adenosine triphosphate (ATP) and a nitrogen source, which makes availability of the molecule highly sensitive to energy and nitrogen availability. However, this type of negative pressure would equally apply to synthesis of ATP, the most abundant nucleotide in the cell (Zhang et al., 2008). This suggests that the organization of anaerobic processes is not suitable per se to modulate the stoichiometry of specific nucleoside triphosphates (NTPs) according to a well-defined pattern. Then, what about their degradation and salvage?

At some point in all life cycles, metabolites are damaged then repaired or degraded then recycled, either as a whole or as parts. In the purine nucleotide salvage pathway, the key enzyme is adenine phosphoribosyltransferase (Wilson et al., 1986). In the same way, guanine is salvaged via hypoxanthine–guanine phosphoribosyltransferase (Balendiran et al., 1999). In pyrimidine salvage, uracil is recycled using uracil phosphoribosyltransferase (Li et al., 2007; blue arrow in Fig. 2). Yet, contrary to expectation, this does not go at all this way with cytosine. Surprisingly, no cytosine phosphoribosyltransferase has been identified in any living organism. For some reason, natural selection avoided retaining a direct route for cytosine salvage, despite that it does not seem difficult to evolve enzyme variants which would catalyse the reaction. The cytosine recycling process begins with converting cytosine-containing metabolites to cytidine then uridine, or cytosine to uracil, which is mainly scavenged directly by uracil phosphoribosyltransferase. Everything goes as if salvage of cytosine nucleotides had to go through deamination of cytosine-containing metabolites to uracil-containing molecules, followed by neosynthesis of UTP- and ATP-dependent amidation to CTP by CTP synthase (PyrG). This unique step is so essential that the pyrG gene is conserved in parasites (Aurrecoechea et al., 2009) and even in the smallest streamlined genome of an autonomous synthetic construct (Hutchison et al., 2016). What’s more, the unique features of cytosine metabolism do not end up there, as CTP synthase displays a very unusual architecture. It forms filaments, named cytoophidia, in all organisms where its organization has been explored (Li et al., 2018). Cytoophidia create a strict compartmentalization of the corresponding activity (Liu, 2010; Sun and Liu, 2019). This organization is linear and therefore satisfies the bottom-up level constraints of non-homothetic growth (i.e., 1-D growth is even more constrained than 2-D growth, which itself is more constrained than 3-D growth), placing CTP uniquely at the crossroad of global metabolic controls.

Correlated with 2-D growth, the synthesis of membrane lipids generates yet a further critical involvement of CTP-dependent metabolism for controlling non-homothetic cell

![Fig. 2. Synthesis and salvage of pyrimidines.](image-url)

In green, the central pyrimidine pathway for biosynthesis. The specific pathway for cytosine derivatives is in red. The dotted arrows mark catabolism. Additional routes are shown with dashed lines: purple for lipid synthesis and green for protein glycosylation. In blue we have shown the key enzyme which allows the recycling of pyrimidines via uracil. The parallel pathway for cytosine has not been discovered in any organism to date. [Correction statement added on 08 May 2020 after first online publication: Figure 2 has been corrected in this version.]

© 2020 Society for Applied Microbiology and John Wiley & Sons Ltd., Environmental Microbiology, 22, 1977–1985
growth. As a matter of fact, the double layer of phospholipids forming most membranes derives from cytosine-based liponucleotides (the raison d'être of cytosine-specific nucleotides in this makeup has not been investigated previously, but control of non-homothetic growth makes it a brilliant choice). This involves a variety of pathways initiated by CDP-diglycerides or chemically related analogues (Chauhan et al., 2016; McMaster, 2018). While the membrane lipid composition differs in the three domains of life, the general organization of the cog-nate pathways is similar, using CTP-dependent enzymes not only to form the lipid bilayer of the membrane but also to control its shape via its curvature (Cornell and Ridgway, 2015). In a metabolic development important in the present context where innate immunity must play a central role (Di Conza and Ho, 2020), CTP-dependent phospholipid synthesis is also essential for the generation of the endoplasmic reticulum (ER; Lagace and Ridgway, 2013).

Finally, as now can be expected because of the importance of cytosine-based metabolites, the need for a specific organization of pyrimidine metabolism is implemented in further specific structures. As a case in point documented in many animal cells, the enzymes required for the onset of the de novo synthesis of pyrimidines, carbamoyl-phosphate synthetase (CPsase), aspartate transcarbamylase (ATCase, and dihydroorotase (DHOase) make a multifunctional structure, known as CAD. All three activities are supported by a single 243-kDa polypeptide that forms hexamers and higher oligomers (Del Caño-Ochoa and Ramón-Maiques, 2020). Remarkably, this multifunctional enzyme is sensitive to proteolysis by caspase during apoptosis, indicating that pyrimidine metabolism is involved in this critical process (Huang et al., 2002). Further in line with the metabolic pathways organization explored here in relation with viral infection, CAD is highly expressed in leukocytes, where it enables Toll-like receptor 8 expression in response to cytidine and single-stranded RNA (Furusho et al., 2019). It was also observed early on that an increase in cytoplasmic CTP accelerated the rate of phosphoplipids synthesis in poliomyelitis-infected cells (Choy et al., 1980). Yet another most significant feature of CAD, relevant to our hypotheses, is that its activity is modulated by a dedicated viral protein during enteroviral infection (Cheng et al., 2020). This should prompt further analysis of pyrimidine metabolism in relation with SARS-CoV-2 infection, in particular looking for virus-encoded functions involved in interference with cytosine metabolism, as we now document.

Back to coronaviruses and the cytosine-sensitivity of their construction, virulence and evolution

The requirement of cytosine nucleotides for the virus' genome and envelope synthesis is inevitably connected to the striking limitation in synthesis of cytosine-based metabolites. The most straightforward consequence of this metabolic design is that there is a force that will keep driving the cytosine content of RNAs to lower values, unless opposing processes (and selection pressure leading to discard organisms with too low cytosine content, for example, because this would create intolerable biases in the amino acid composition of the proteins coded by these genomes) had the upper hand during evolution. Coronaviruses, and other positive-sense single-stranded RNA viruses, produce plus strands at a 50- to 100-fold excess of their minus-strand replicated template. A further consequence of the replication process, however unsymmetrical, is that any pressure on a given base availability—here C—would affect its complement—G in our case—as noted above (Fig. 1). The mutations ordained to occur as the virus evolves will therefore reflect both the physicochemical forces acting during replication (typically triggered by cytosine deamination and reactions involving reactive species, resulting in formation of 8-oxoguanine, for example) and the metabolic setup of the host. As discussed in the previous sections, we expect a general selection pressure operating on CTP and tending, in the long run, to decrease the C content of the RNA virus. This is certainly qualified, however, by direct selection pressure on the functions that drive virus replication and propagation and operate on the corresponding codons, hence proteins. This is particularly important for the proline residue, encoded by CCN codons and essential in the folding of key viral protein domains (Li et al., 2014). The presence of a four codon insertion in the spike protein of SARS-CoV-2 is a case in point (Li et al., 2020). The C at the second codon position is also required to allow introduction of threonine or alanine residues in the viral proteins, while the first position is required for histidine and glutamine coding. In this context, it seems relevant to note that, in the SARS-CoV-1 in 2003, one of the critical changes with respect to innocuous counterparts was a leucine to alanine change at the junction between domains S1 and S2 of the spike protein and that this required a U to C change (Song et al., 2005).

Now comes an extraordinary feature that accounts for the way animals control RNA virus diseases via innate immunity. It happens that the unique role of cytosine as a coordinator of global metabolism has been exploited by natural selection to endow hosts with antiviral processes based on interference with the metabolic involvement of this nucleobase. At least three responses have evolved in animals to further prevent virus multiplication, building up an efficient innate antiviral immunity based on cytosine metabolism. Animals, in particular but this extends even to oysters (Green et al., 2014), have recruited an AdoMet-dependent biosynthesis pathway to construct a mimic of CTP, 3'-deoxy-3',4'-didehydro-CTP (ddhCTP, Fig. 3), using an enzyme named viperin, for virus inhibitory protein, ER-associated, interferon-inducible (Duchsche and Broderick,
Cytosine drives evolution of SARS-CoV-2

Viperin-derived ddhCTP and N4-hydroxy-cytidine. ddhCTP is the natural antimetabolite of the innate antiviral defence metabolite produced by viperin. N4-hydroxy-cytidine analogues are often chosen as antiviral candidates, but if their chemical properties lead them to produce N4-hydroxy-cytidine, the molecule will be immediately phosphorylated and lead to a potent mutagen. Great care must therefore be taken when choosing the nucleoside analogues used as antivirals.

**Fig. 3.** Viperin-derived ddhCTP and N4-hydroxy-cytidine. ddhCTP is the natural antimetabolite of the innate antiviral defence metabolite produced by viperin. N4-hydroxy-cytidine analogues are often chosen as antiviral candidates, but if their chemical properties lead them to produce N4-hydroxy-cytidine, the molecule will be immediately phosphorylated and lead to a potent mutagen. Great care must therefore be taken when choosing the nucleoside analogues used as antivirals.
trend toward a loss of C residues should lead to attenuation, it may have been used as a natural mechanism for the virus to escape innate immunity, at least during the first steps of evolution of the pathogens. Indeed, the very fact that the genomes lose progressively their cytosines, in particular in CpG dinucleotides, allow them to escape the ZAP and Dnmt2 innate immunity, while less C will also give less room for ddhCTP to interfere with replication. However the latter effect is probably less of a concern because ddhCTP will still interfere with the construction of the viral envelope. In the long term, however, a progressive loss of C in the genome will deplete the proteins it encodes in alanine, histidine, glutamine, proline and threonine, thus narrowing considerably the evolutionary landscape of the pathogen.

Based on a loose analogy with computer viruses, which hack operating systems by tapping into “system resources,” yet another feature critical to anticipate the ultimate evolution of RNA viruses is as follows. Natural selection is based on the existence of functions that are a posteriori found to benefit the future of any species. When a biochemical function is implemented—here the control of nucleotide metabolism via cytosine nucleotides synthesis and salvage—its nullification is open to positive selection. This implies that we should look for RNA viruses that have overcome this limitation and look for guanine–cytosine (GC)-rich RNA viruses. Some exist, as the rubella viruses, which have genomes in the 70% GC range (Zhu et al., 2016). There is no straightforward indication that they code for systems that interfere with CTP metabolism. However, despite the limited length of their genome (approximately one third of that of coronaviruses), the 3' half of their genome codes for unknown functions associated to proteins of the capsid—hence immediately available upon infection—that have been shown to interact with the host cell’s machinery in regions certainly connected to metabolism (Zheng and Kielian, 2013). An obvious experimental program derived from the present hypothesis would be, therefore, to set up experiments to explore this possibility. This would considerably improve our knowledge of the way viruses develop.

We are well aware of the limitations of the present study, due to the small number of samples and fairly short time span of the present epidemic. However we feel that, in view of the urgent situation we are facing with the COVID-19 pandemic, it is important to communicate our observations while relating them to previously unrecognized pressure that must have considerable importance in the evolution of viruses and in the design or new treatments.

A cautionary note: Primum non nocere

The emergence of ddhCTP as an antiviral selected by evolution as an innate immunity weapon shows us a path to follow. We should however take great caution in the development of nucleoside analogues as therapeutic agents. The effectiveness of such molecules, sometimes called antinucleosides, may come from the fact that they inhibit directly the activity of a viral enzyme, for example by blocking the activity of replicases. A completely different scenario arises when an antinucleoside is converted by metabolic enzymes of the host into a substrate of viral enzymes, such as a chemically altered analogue of the NTPs, CTP or ATP, for example. The incorporation by the replicase of the antinucleoside into the RNA of the virus will stop its proliferation, as anticipated. This could be by interrupting the elongation of the replicated RNA chain, we then speak of a “chain terminator.” As discussed above, this is one of the antiviral mechanisms observed for the viperin product. Alternatively, this could result from incorporating ambivalent nucleobases into the viral genome, allowing pairing with more than one canonical base. Such ambivalent antinucleosides literally lead to blurring the genetic message of the virus while it replicates, as we have learned from the use of ribavirin, which requires its activation into a triphosphate to sabotage the proliferation of riboviruses (Tanaka et al., 2019). In the same way, the mechanism of action of favipiravir is understood to combine the two effects of pairing ambivalence and chain termination once it is converted into its nucleoside triphosphate counterpart (Furuta et al., 2017).

Yet, once input in the viral genome, these analogues will be readily converted to nucleoside monophosphates and diphosphates which will be processed by the host cell’s metabolism. The diphosphate analogues will be converted, via the enzyme ribonucleoside diphosphate reductase, into deoxyribonucleoside diphosphates, then triphosphates, and get into the cell’s genome (Fig. 2). This creates a situation where agents of these antiviral families will lead to alterations in the human DNA, i.e., accumulate somatic or germinal mutations leading to cancer, foetal malformations or hereditary diseases, all conditions that cannot be observed in the short term. Alas, the standard course of clinical trials does not easily involve long-term observations, especially in times of emergency. As a consequence, we strongly recommend that mutagenesis tests be carefully performed during the validation procedures required for identification of antivirals directed against SARS-CoV-2. For example, the bacteriological literature is replete with data demonstrating the highly mutagenic nature of N4-hydroxy-cytidine (Sledziewska and Janion, 1980; Fig. 3, as well as homologous structures N4-methoxy-cytidine, N4-amino-cytidine, etc.) via their conversion into its deoxynucleoside triphosphate counterpart. Health authorities should therefore be aware of the long-term risk of compounds capable of delivering these mutagenic nucleosides, such as EIDD-2801 (Sheahan et al., 2020), regardless of their antiviral efficacy.
Acknowledgements

This work benefited from discussions with members of the Stanislas Noria seminar and from critical comments of Pierre-Yves Bourguignon, Félix Rey and Ken Timmis. AD is CSO of the company Kodikos Labs, and PHM is president of TESSSI and director of TheraXen SA.

Note added in proof

An article supporting the role of CpG dinucleotides in the evolution of SARS-CoV-2 appeared after the present article was submitted for publication: Xuhua Xia Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense. *Molecular Biology and Evolution*, msaa094, https://doi.org/10.1093/molbev/msaa094

References

Arribas, M., Aguirre, J., Manrubia, S., and Lázaro, E. (2018) Differences in adaptive dynamics determine the success of virus variants that propagate together. *Virus Evol* 4: vex043.

Aurrecoechea, C., Brestelli, J., Brunk, B.P., Carlton, J.M., Dommer, J., Fischer, S., et al. (2009) GiardiaDB and TrichDB: integrated genomic resources for the eukaryotic protist pathogens *Giardia lamblia* and *Trichomonas vaginalis*. *Nucleic Acids Res* 37: D526–D530.

Balendiran, G.K., Molina, J.A., Xu, Y., Torres-Martinez, J., Stevens, R., Focia, P.J., et al. (1999) Ternary complex structure of human HGPRTTase, pRpp, Mg2+, and the inhibitor HPP reveals the involvement of the flexible loop in substrate binding. *Protein Sci* 8: 1023–1031.

Bemingham, A., Chand, M.A., Brown, C.S., Aarons, E., Tong, C., Langrish, C., et al. (2012) Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, in September 2012. *Euro Surveill* 17: 20290.

Bohnsack, K.E., Höbartner, C., and Bohnsack, M.T. (2019) Eukaryotic 5-methylcytosine (m5C) RNA methyltransferases: mechanisms, cellular functions, and links to disease. *Genes (Basel)* 10: E102.

Chauhan, N., Farine, L., Pandey, K., Menon, A.K., and Bütikofer, P. (2016) Lipid topogenesis of virus variants that propagate together. *Virus Evol* 4: vex043.

Chen, Y., Liu, Q., and Guo, D. (2020) Emerging coronaviruses: genome structure, replication, and pathogenesis. *J Med Virol* 92: 418–423.

Cheng, M.-L., Chien, K.-Y., Lai, C.-H., Li, G.-J., Lin, J.-F., and Ho, H.-Y. (2020) Metabolic reprogramming of host cells in response to enteroviral infection. *Cell* 9: E473.

Chin, K.C., and Cresswell, P. (2001) Viperin (cig), an IFN-inducible antiviral protein directly induced by human cyto- megalovirus. *Proc Natl Acad Sci U S A* 98: 15125–15130.

Choy, P.C., Paddon, H.B., and Vance, D.E. (1980) An increase in cytoplasmic CTP accelerates the reaction catalyzed by CTP:phosphocholine cytidylyltransferase in poliovirus-infected HeLa cells. *J Biol Chem* 255: 1070–1073.

Cornell, R.B., and Ridgway, N.D. (2015) CTP:phosphocholine cytidylyltransferase: function, regulation, and structure of an amphitropic enzyme required for membrane biogenesis. *Prog Lipid Res* 59: 147–171.

Del Caño-Ochoa, F., and Ramón-Maíques, S. (2020) The multienzymatic protein CAD leading the de novo biosynthesis of pyrimidines localizes exclusively in the cytoplasm and does not translocate to the nucleus. *Nucleosides Nucleotides Nucleic Acids*. https://doi.org/10.1080/15257770.2019.1706743.

Dev, R.R., Ganji, R., Singh, S.P., Mahalingam, S., Banerjee, S., and Khosla, S. (2017) Cytosine methylation by DNMT2 facilitates stability and survival of HIV-1 RNA in the host cell during infection. *Biochem J* 474: 2009–2026.

Di Conza, G., and Ho, P.-C. (2020) ER stress responses: an emerging modulator for innate immunity. *Cell* 9: E695.

Du, Y.-X., and Chen, X.-P. (2020) Favipiravir: pharmacokinet-ics and concerns about clinical trials for 2019-nCoV infection. *Clin Pharmacol Ther* (in press). https://doi.org/10.1002/cpt.1844.

Dukhovny, A., Shlomai, A., and Sklan, E.H. (2018) The antiviral protein Viperin suppresses T7 promoter dependent RNA synthesis-possible implications for its antiviral activity. *Sci Rep* 8: 8100.

Durdevic, Z., Hanna, K., Gold, B., Pollex, T., Cherry, S., Lyko, F., and Schaefer, M. (2013) Efficient RNA virus control in drosophila requires the RNA methyltransferase Dnmt2. *EMBO Rep* 14: 269–275.

Duschen, K.S., and Broderick, J.B. (2010) The antiviral protein viperin is a radical SAM enzyme. *FEBS Lett* 584: 1263–1267.

Ebrahimi, K.H., Howie, D., Rowbotham, J., McCullagh, J., Armstrong, F., and James, W.S. (2020) Viperin, through its radical-SAM activity, depletes cellular nucleotide pools and interferes with mitochondrial metabolism to inhibit viral replication. *FEBS Lett* (in press). https://doi.org/10.1002/1873-3468.13761.

Fang, J., Wang, H., Bai, J., Zhang, Q., Li, Y., Liu, F., and Jiang, P. (2016) Monkey viperin restricts porcine reproductive and respiratory syndrome virus replication. *PLoS One* 11: e0156513.

Ficarelli, M., Antzin-Anduetza, I., Hugh-White, R., Firth, A.E., Sertkaya, H., Wilson, H., et al. (2020) CpG dinucleotides inhibit HIV-1 replication through zinc finger antiviral protein (ZAP)-dependent and -independent mechanisms. *J Virol* 94: e01337-19.

Fordsyke, D.R., and Mortimer, J.R. (2000) Chargaff’s legacy. *Gene* 261: 127–137.

Furusho, K., Shibata, T., Sato, R., Fukui, R., Motoi, Y., Zhang, Y., et al. (2019) Cytidine deaminase enables toll-like receptor 8 activation by cytidine or its analogs. *Int Immunol* 31: 167–173.

Furuta, Y., Komeno, T., and Nakamura, T. (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. *Proc Jpn Acad Ser B Phys Biol Sci* 93: 449–463.

Gizzi, A.S., Grove, T.L., Arnold, J.J., Jose, J., Jangra, R.K., Garforth, S.J., et al. (2018) A naturally occurring antiviral ribonucleotide encoded by the human genome. *Nature* 558: 610–614.
Green, T.J., Benkendorff, K., Robinson, N., Raftos, D., and Speck, P. (2014) Anti-viral gene induction is absent upon secondary challenge with double-stranded RNA in the Pacific oyster, Crassostrea gigas. Fish Shellfish Immunol 39: 492–497.

Huang, M., Kozlowski, P., Collins, M., Wang, Y., Haystead, T.A., and Graves, L.M. (2002) Caspase-dependent cleavage of carbamoyl phosphate synthetase II during apoptosis. Mol Pharmacol 61: 569–577.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497–506.

Hutchison, C.A., Chuang, R.-Y., Noskov, V.N., Assad-Garcia, N., Deerinck, T.J., Ellisman, M.H., et al. (2016) Design and synthesis of a minimal bacterial genome. Science 351: aad6253.

Jee, Y. (2020) WHO international health regulations emergency committee for the COVID-19 outbreak. Epidemiol Health 42: e2020013.

Kaiser, S., Jurkowski, T.P., Kellner, S., Schneider, D., Jeltsch, A., and Helm, M. (2017) The RNA methyltransferase Dnmt2 methylates DNA in the structural context of a tRNA. RNA Biol 14: 1241–1251.

Kuo, L., Koetzner, C.A., and Masters, P.S. (2016) A key role for the carboxy-terminal tail of the murine coronavirus nucleocapsid protein in coordination of genome packaging. Virology 494: 100–107.

Kutnjak, D., Elena, S.F., and Ravnikar, M. (2017) Time-sampled population sequencing reveals the interplay of selection and genetic drift in experimental evolution of potato virus Y. J Virol 91: e00690-17.

Lagace, T.A., and Ridgway, N.D. (2013) The role of phospholipids in the biological activity and structure of the endoplasmic reticulum. Biochim Biophys Acta 1833: 2499–2510.

Lee, J., and Ridgway, N.D. (2020) Substrate channeling in the glycerol-3-phosphate pathway regulates the synthesis, storage and secretion of glycolipids. Biochim Biophys Acta Mol Cell Biol Lipids 1865: 158438.

Li, J., Huang, S., Chen, J., Yang, Z., Fei, X., Zheng, M., et al. (2007) Identification and characterization of human uracil phosphoribosyltransferase (UPRTase). J Hum Genet 52: 415–422.

Li, Y., Sunya, W., Claudine, S., and Torres, J. (2014) Structure of a conserved Golgi complex-targeting signal in coronavirus envelope proteins. J Biol Chem 289: 12535–12549.

Li, H., Ye, F., Ren, J.-Y., Wang, P.-Y., Du, L.-L., and Liu, J.-L. (2018) Active transport of cytophilia in Schizosaccharomyces pombe. FASEB J 32: 5891–5898.

Li, X., Zai, J., Zhao, Q., Nie, Q., Li, Y., Foley, B.T., and Chaillon, A. (2020) Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. J Med Virol (in press). https://doi.org/10.1002/jmv.25731

Liu, J.-L. (2010) Intracellular compartmentation of CTP synthase in drosophila. J Genet Genomics 37: 281–296.

Luo, X., Wang, X., Gao, Y., Zhu, J., Liu, S., Gao, G., and Gao, P. (2020) Molecular mechanism of RNA recognition by zinc-finger antiviral protein. Cell Rep 30: 46–52 e4.

Mayer, K.A., Stöckl, J., Zlabinger, G.J., and Gualdoni, G.A. (2019) Hijacking the supplies: metabolism as a novel facet of virus-host interaction. Front Immunol 10: 1533.

McMaster, C.R. (2018) From yeast to humans - roles of the Kennedy pathway for phosphatidylcholine synthesis. FEBS Lett 592: 1256–1272.

Orton, R.J., Wright, C.F., King, D.P., and Haydon, D.T. (2020) Estimating viral bottleneck sizes for FMDV transmission with and between hosts and implications for the rate of viral evolution. Interface Focus 10: 20190066.

Park, M., Cook, A.R., Lim, J.T., Sun, Y., and Dickens, B.L. (2020) A systematic review of COVID-19 epidemiology based on current evidence. J Clin Med 9: E967.

Sawicki, S.G., Sawicki, D.L., and Siddell, S.G. (2007) A contemporary view of coronavirus transcription. J Virol 81: 20–29.

Schilling, C.H., Edwards, J.S., and Palsson, B.O. (1999) Toward metabolic genomics: analysis of genomic data using flux balances. Biotechnol Prog 15: 288–295.

Seo, J.-Y., and Cresswell, P. (2013) Viperin regulates cellular lipid metabolism during human cytomegalovirus infection. PLoS Pathog 9: e1003497.

Sexton, N.R., Smith, E.C., Blanc, H., Vignuzzi, M., Peersen, O.B., and Denison, M.R. (2016) Homology-based identification of a mutation in the coronavirus RNA-dependent RNA polymerase that confers resistance to multiple mutagens. J Virol 90: 7415–7428.

Sheahan, T.P., Sims, A.C., Zhou, S., Graham, R.L., Pruijssers, A.J., Agostini, M.L., et al. (2020) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 06 Apr 2020: eabb5883.

Siedleweska, E., and Janion, C. (1980) Mutagenic specificity of N4-hydroxycoxcytidine. Mutat Res 70: 11–16.

Song, H.-D., Tu, C.-C., Zhang, G.-W., Wang, S.-Y., Zheng, K., Lei, L.-C., et al. (2005) Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci USA 102: 2430–2435.

Sun, Z., and Liu, J.-L. (2019) mTOR-S6K1 pathway mediates cytophodium assembly. J Genet Genomics 46: 65–74.

Tanaka, Y., Inoue, A., Mizunuma, T., Matsumura, H., Yokomori, H., Komiya, T., and Otori, K. (2019) Tolerance of erythrocyte ribavirin triphosphate concentrations depends on the ITPA genotype. Ther Drug Monit 41: 497–502.

Thiagarajan, D., Dev, R.R., and Khosla, S. (2011) The DNA methyltransferase Dnmt2 participates in RNA processing for the carboxy-terminal tail of the murine coronavirus nucleocapsid protein in coordination of genome packaging. Virology 494: 100–107.

Kunin, G., and Danchin, A. (2007) The SARS case study: an alarm clock? In Encyclopedia of Infectious Diseases, Tibayrenc, M. (ed). Hoboken, NJ: John Wiley & Sons, Inc., pp. 151–162.

Udugama, B., Kadhiresan, P., Kozlowski, H.N., Malekjahani, A., Osborne, M., Li, V.Y.C., et al. (2020) Diagnosing COVID-19: the disease and tools for detection. ACS Nano (in press). https://doi.org/10.1021/acsnano.0c02624

Wei, C., Zheng, C., Sun, J., Luo, D., Tang, Y., Zhang, Y., et al. (2018) Viperin inhibits enterovirus A71 replication by interacting with viral 2C protein. Viruses 10: E13.

Wellen, K.E., and Thompson, C.B. (2012) A two-way street: reciprocal regulation of metabolism and signalling. Nat Rev Mol Cell Biol 13: 270–276.

Wilson, J.M., O’Toole, T.E., Argos, P., Shewach, D.S., Daddona, P.E., and Kelley, W.N. (1986) Human adenine
phosphoribosyltransferase. Complete amino acid sequence of the erythrocyte enzyme. *J Biol Chem* **261**: 13677–13683.

Woods, P.S., Doolittle, L.M., Rosas, L.E., Joseph, L.M., Calomeni, E.P., and Davis, I.C. (2016) Lethal H1N1 influenza virus infection alters the murine alveolar type II cell surfactant lipidome. *Am J Physiol Lung Cell Mol Physiol* **311**: L1160–L1169.

Zhang, Y., Burke, C.W., Ryman, K.D., and Klimstra, W.B. (2007) Identification and characterization of interferon-induced proteins that inhibit alphavirus replication. *J Virol* **81**: 11246–11255.

Zhang, Y., Morar, M., and Ealick, S.E. (2008) Structural biology of the purine biosynthetic pathway. *Cell Mol Life Sci* **65**: 3699–3724.

Zheng, J., Zeng, H., Gu, J., Li, H., Zheng, L., and Zou, Q. (2020) Progress and prospects on vaccine development against SARS-CoV-2. *Vaccines (Basel)* **8**: E153.

Zhang, Y., and Kielian, M. (2013) Imaging of the alphavirus capsid protein during virus replication. *J Virol* **87**: 9579–9589.

Zhu, Z., Chen, M., Abernathy, E., Icenogle, J., Zhou, S., Wang, C., et al. (2016) Analysis of complete genomes of the rubella virus genotypes 1E and 2B which circulated in China, 2000–2013. *Sci Rep* **6**: 39025.

Zhu, M., Zhou, J., Liang, Y., Nair, V., Yao, Y., and Cheng, Z. (2020) CCCH-type zinc finger antiviral protein mediates antiviral immune response by activating T cells. *J Leukoc Biol* **107**: 299–307.